company background image
VIR

Vir BiotechnologyNasdaqGS:VIR Stock Report

Market Cap

US$5.4b

7D

6.4%

1Y

15.4%

Updated

25 Oct, 2021

Data

Company Financials +
VIR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VIR Overview

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Vir Biotechnology
Historical stock prices
Current Share PriceUS$41.27
52 Week HighUS$25.31
52 Week LowUS$141.01
Beta-1.31
1 Month Change-5.82%
3 Month Change13.26%
1 Year Change15.38%
3 Year Changen/a
5 Year Changen/a
Change since IPO194.37%

Recent News & Updates

Sep 13
We're Not Worried About Vir Biotechnology's (NASDAQ:VIR) Cash Burn

We're Not Worried About Vir Biotechnology's (NASDAQ:VIR) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

VIRUS BiotechsUS Market
7D6.4%2.7%1.9%
1Y15.4%18.8%33.4%

Return vs Industry: VIR matched the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: VIR underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is VIR's price volatile compared to industry and market?
VIR volatility
VIR Beta-1.31
Industry Beta0.98
Market Beta1

Stable Share Price: VIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: VIR's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016367George Scangoshttps://www.vir.bio

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd.

Vir Biotechnology Fundamentals Summary

How do Vir Biotechnology's earnings and revenue compare to its market cap?
VIR fundamental statistics
Market CapUS$5.39b
Earnings (TTM)-US$297.36m
Revenue (TTM)US$182.71m

29.5x

P/S Ratio

-18.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VIR income statement (TTM)
RevenueUS$182.71m
Cost of RevenueUS$344.89m
Gross Profit-US$162.17m
ExpensesUS$135.19m
Earnings-US$297.36m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 04, 2021

Earnings per share (EPS)-2.28
Gross Margin-88.76%
Net Profit Margin-162.74%
Debt/Equity Ratio0%

How did VIR perform over the long term?

See historical performance and comparison

Valuation

Is Vir Biotechnology undervalued compared to its fair value and its price relative to the market?

7.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VIR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VIR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VIR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VIR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VIR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VIR is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Vir Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-27.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VIR's revenue (22% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: VIR's revenue (22% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VIR is forecast to be unprofitable in 3 years.


Past Performance

How has Vir Biotechnology performed over the past 5 years?

-43.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIR is currently unprofitable.

Growing Profit Margin: VIR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VIR is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.

Accelerating Growth: Unable to compare VIR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: VIR has a negative Return on Equity (-40.33%), as it is currently unprofitable.


Financial Health

How is Vir Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: VIR's short term assets ($862.3M) exceed its short term liabilities ($146.0M).

Long Term Liabilities: VIR's short term assets ($862.3M) exceed its long term liabilities ($174.2M).


Debt to Equity History and Analysis

Debt Level: VIR is debt free.

Reducing Debt: VIR had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VIR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VIR has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 20% each year.


Dividend

What is Vir Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

George Scangos (73 yo)

4.75yrs

Tenure

US$994,883

Compensation

Dr. George A. Scangos, Ph D., serves as the Chief Executive Officer, President and Director of Vir Biotechnology, Inc. since January 2017. Dr. Scangos served as the Chief Executive Officer of Biogen Idec L...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD994.88K) is below average for companies of similar size in the US market ($USD6.33M).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VIR's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: VIR's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

Vir Biotechnology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Vir Biotechnology, Inc.
  • Ticker: VIR
  • Exchange: NasdaqGS
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.390b
  • Shares outstanding: 130.61m
  • Website: https://www.vir.bio

Number of Employees


Location

  • Vir Biotechnology, Inc.
  • 499 Illinois Street
  • Suite 500
  • San Francisco
  • California
  • 94158
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 23:24
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.